New analysis of IAVI G001 trial shows nanoparticle HIV vaccine creates strong immune response in helper T cells.
Features
Expanded access would benefit many in low- and middle-income countries.
April 28, 2023
IAVI Board member and ICAP founder Wafaa El-Sadr recognized for her contributions to global health.
March 30, 2023
Presentations will focus on vaccines for HIV, neglected diseases, and pandemic preparedness.
March 27, 2023
Denmark, represented by the Danish Ministry of Foreign Affairs is committed to contribute a total of DKK 20 million (US$3 million) from 2022-2025.
Strengthening research and science leadership capacity of early- and mid-career research scientists in Africa and India.
March 7, 2023
IAVI and WomenLift Health explore why investing in women’s leadership development in science is beneficial to global health research.
A new brief calls on decision-makers to prioritize tuberculosis vaccine R&D in all global health and antimicrobial resistance agendas.
February 22, 2023
The Ministry will award IAVI €21 million over the next five years as part of the Product Development Partnership IV Fund.
February 7, 2023
Three regulatory experts discuss alternative approaches for demonstrating the effectiveness of vaccines against deadly filoviruses.
January 30, 2023
New IAVI white paper identifies critical gaps across R&D, equitable access, and financing.
Show More
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
